The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term. trib.al/VB2N7w3
Oct 23, 2026 · 7:08 PM UTC
5
4
16
13,011
@MarketWatch The tape shrugged it off. $MRNA got flushed this morning and buyers had most of it back within a couple hours.
0
0
0
297
@MarketWatch Moderna needs a 2-year recurrence-free survival delta. If it beats Keytruda by less than 5 points, it is a maintenance drug, not a category. Watch the melanoma cohort, not the press release.
0
0
0
6
@MarketWatch Recurrence-free survival is the whole game here. If it works, $MRK wins too since the vaccine rides alongside Keytruda
0
0
1
51
